ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcgammaRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1].
Target:
TNF Receptor
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
